Share on LinkedInShare on LinkedIn

ARTICLE · 02 APRIL 2021

Competition And Markets Authority v Flynn Pharma Limited

Bristows LLP
Bristows LLP
Contributor
Bristows LLP

Bristows LLP

We are Bristows, the world’s leading specialist law firm for clients that innovate. We are a London...

View firm profile
Explore more from Bristows LLP

The Court of Appeal gave judgment in Competition and Markets Authority v Flynn Pharma and Pfizer in May 2020, effectively adjusting the starting point for costs awards following successful appeals of CMA decisions.

United KingdomAntitrust/Competition Law

The Court of Appeal gave judgment in Competition and Markets Authority v Flynn Pharma and Pfizer in May 2020, effectively adjusting the starting point for costs awards following successful appeals of Competition and Markets Authority (CMA) decisions. Following this judgment, such awards by the Competition Appeal Tribunal (CAT) must start from the position that no order as to costs should be made against the CMA, rather than the standard approach of 'costs follow the event' that had been the CAT's established practice.

Sophie Lawrance and Aimee Brookes explore the rationale for the CAT's past practice, the basis for the Court of Appeal's judgment altering that approach, and considers the potential implications the judgment may have.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from